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Summary
Dogs are sometimes referred to as “man’s best friend” and with the increase in urbanization and lifestyle 
changes, dogs are seen by their owners as family members. Society expresses specific concerns about  
the experimental use of dogs, as they are sometimes perceived to have a special status for humans. This 
may appear somewhat conflicting with the idea that the intrinsic value of all animals is the same, and that 
also several other animal species are used in biomedical research and toxicology. This aspect and many 
others are discussed in an introductory chapter dealing with ethical considerations on the use of dogs 
as laboratory animals. The report gives an overview on the use of dogs in biomedical research, safety 
assessment and the drug developmental process and reflects the discussion on the use of dogs as second 
(non-rodent)species in toxicity testing. Approximately 20,000 dogs are used in scientific procedures in 
Europe every year, and their distinct genetic, physiological and behavioral characteristics may support 
their use as models for e.g. behavioral analysis and genetic research. Advances in the 3Rs (Replacement, 
Reduction and Refinement of experiments using dogs) are described, potential opportunities are  
discussed and recommendations for further progress in this area are made.
 
Keywords: dog use, animal welfare, moral dilemma, second species paradigm, 3Rs
*a report of t4 – the transatlantic think tank for toxicology, a collaboration of the toxicolgically oriented chairs in Baltimore, Konstanz and Utrecht 
sponsored by the Doerenkamp-Zbinden Foundation
† This workshop was held in memory of Hildegard Doerenkamp (1920 – 2011), the philanthropic cofounder of the Doerenkamp-Zbinden Foundation. 
report reflects the presentations given by the participants, some 
background information, and the discussions and recommenda-
tions of the workshop. It is not a consensus report, but shows 
the spectrum of views. Participants took part in the workshop 
because of their personal background and expertise, not as rep-
resentatives of their organizations. 
2  About dogs…
early domestication is thought to have occurred when humans 
captured young wolves and selectively bred those that were tame 
1  Introduction
the workshop on “Critical evaluation of the Use of Dogs in 
Biomedical Research and testing” hosted by the Centre for Al-
ternatives to Animal testing (CAAt-europe) and the transatlan-
tic think tank for toxicology (t4) took place on June 21-23, 2011 
in Budapest, Hungary, and was sponsored by the Doerenkamp-
Zbinden Foundation (DZF). Participants from industry, animal 
welfare organizations, the regulatory arena and academia came 
together to discuss the current use of dogs, the regulatory back-
ground, ethical issues, and opportunities to replace, reduce and 
refine the use of dogs in biomedical research and testing. This 
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and sociable, so that human interaction played a significant role 
in shaping the subspecies (Miklosi, 2007). Domestic dogs have 
been selectively bred for various behaviors, capabilities, and 
physical attributes (Dewey and Bhagat, 2002). In the past the 
relationship between humans and dogs was often more practical 
and so humans provided food, shelter and social contacts, while 
the dog contributed by herding, protection and hunting. Pet dog 
populations grew significantly after World War II as urbaniza-
tion increased (Derr, 2004) and in the 1950s and 1960s, dogs 
were still kept outside more often than today (Franklin, 2006). 
In many Western countries and Japan dogs are now included in 
families and homes (Power, 2008).
In europe approximately 62 million households own at least 
one pet, and it is estimated that these include 60 million cats and 
56 million dogs1. It is well established that the companionship 
of a pet can enhance human physical health and psychological 
well-being by reducing stress and blood pressure (Podberscek, 
2006). Pet owners have been shown to have better mental and 
physical health, making fewer visits to the doctor and being less 
likely to be on medication than non-owners (Headey, 1999).
Dogs are also used to help disabled people: in europe some 
13,000 guide dogs assist the blind, the deaf and people with 
physical disabilities. they are also trained as disaster dogs to 
help after earthquakes or avalanches, as police dogs, searching 
for missing people or for security tasks such as finding explo-
sives and drugs2.
Pets even create their own market for food and care acces-
sories. According to a FeDIAF (european Pet Food Industry) 
“Facts & Figures” document3 the sales of pet food and other 
related products and services has a turnover of € 24 billion with 
a growth rate of 2% annually.
When describing the dog’s role in society it should be men-
tioned that there are cultural differences. For example, in some 
east Asian countries, including Korea, China, and Vietnam, dog 
meat is eaten by humans and it is estimated that 13-16 million 
dogs are consumed in Asia every year4 – a practice that dates 
back to antiquity.
3  The animal welfare perspective
the Sixth Report5 from the european Commission on the number 
of animals used for experimental and other scientific purposes in 
the Member States of the european Union in 2008 states that 12.2 
million vertebrates were used including 21,315 dogs. 
the protection of animals, as anchored in the eU treaty of 
Amsterdam of 1999, and amended by the treaty of lisbon in 
2009, is a major goal that the Union should respect: “In formu-
lating and implementing the Union’s agriculture, fisheries, trans-
port, internal market, research and technological development 
and space policies, the Union and the Member States shall, since 
animals are sentient beings, pay full regard to the welfare re-
quirements of animals, while respecting the legislative or admin-
istrative provisions and customs of the Member States relating 
in particular to religious rites, cultural traditions and regional 
heritage.” this is also the major goal of the Directives 86/609/
eeC and 2010/63/eU (Hartung et al., 2010a) on the protection 
of animals used for scientific purposes, the European Conven-
tion etS 123 and the individual Animal Welfare Acts of the eU 
Member States. the Community Action Plan 2006-2010 and the 
eU Strategy for Protection and Welfare of animals 2011-2015 to 
be adopted in December 2011 will further this goal6. 
From an animal welfare perspective, concerns arise from 
the fact that animal experiments cause pain, distress and harm. 
Housing may restrict “natural” behavior and some animals may 
develop dysfunctional behaviors. Stressors can also include oth-
er issues, such as transport. Moral concerns as well are raised 
by the fact that in most cases the animal is euthanized at the end 
of a procedure, although in some cases dogs may be retired and 
re-homed. 
Further, the discussion regarding the benefits of animal re-
search for humans (Hartung, 2008a) still is controversial. A final 
goal of 3Rs developments should be to replace all animal ex-
periments by scientifically valid human cell or other models, but 
where this is not possible the other principles of “Reduction” 
and “Refinement” should be applied. The public is particularly 
concerned about the use of distinct animal species, such as dogs 
and monkeys, and some argue that these species should be given 
special protection. Although some legislation, such as the UK 
Animals (Scientific Procedures) Act from 1986 does make such 
special provisions for dogs, others do not.
there is little public information available about the use of 
dogs; therefore, a survey was carried out by the Doerenkamp-
Zbinden foundation in six randomly chosen european countries 
over the period from 2004-2006 on publicly available informa-
tion, taking into account the eC Report as well as online search 
tools like PubMed and Google Scholar. Very limited informa-
tion could be retrieved, for example on the detail of experimen-
tal procedures, making it impossible for the public to assess the 
severity of experiments, numbers of animals used in any par-
ticular experiment and the level of pain and distress inflicted.
the number of animals used is known from public statistics, 
but the procedures used on the animals cannot be found in the 
scientific literature. Publications from the six surveyed coun-
tries, which represented roughly half of the eU animal use in re-
search, accounted for only 800 of the approximately 20,000 dogs 
used in europe, most probably due to the following points:
– Not all papers are published in english.
– experiments are often not published when they have not pro-
duced positive results or were aborted.
– experiments that are performed in private laboratory facili-
ties and/or companies, where the results are used to fulfill le-
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order to deliver solutions to perceived welfare issues, animal 
welfare scientists must take both the societal perception and sci-
entifically based considerations into account: The recommenda-
tions they make regarding animal welfare issues must comply 
with the moral values of society in order to generate sustainable 
approaches. For doing so, a systematic approach is needed to 
identify potential moral dilemmas in animal welfare and factors 
that might influence these dilemmas. The Dutch Animal Wel-
fare Council recently developed such an approach, the so-called 
ethical framework7, demonstrated in Figure 1, to structure dis-
cussions about the ethical dimension of current and potential 
future animal welfare issues. Such a discussion should cover 
what needs to be done from a moral perspective in any given 
situation, identify relevant ethical issues (specifically in relation 
to animal welfare), and outline the steps that need to be taken to 
resolve these issues. It should be clear that such a framework is 
intended to identify relevant ethical issues and potential moral 
dilemmas rather than to yield straightforward solutions. Fur-
gal requirements, are submitted to the respective authorities 
rather than being published in the peer-reviewed literature.
– experiments published in the cited year might have been car-
ried out long before the year of publication.
to support ethical committees and prevent duplication of pro-
cedures an easily accessible online database might be useful, 
where research facilities can share their data. this was consid-
ered an attractive idea by most of the workshop participants, but 
the practical difficulties might be huge. Most of the pharmaceu-
tical testing is done on new compounds, so the comparison of 
data might be difficult. A certain degree of privacy protection 
might help to overcome most of the other concerns.
4  Moral dilemma
the current relevance of animal welfare issues is strongly 
based on societal concerns about how animals are treated. In 




The aim of this 
framework (adopted 
from RDA, 2010) is to 
structure discussions 
about the ethics of 
the use of dogs as 
experimental animals. 
Such discussions 
should cover what 
we should do from 
a moral perspective 
in a given situation, 
identify relevant 
ethical issues, and 
outline the steps that 
need to be taken to 
resolve this issue 
(kindly provided 
by Frauke Ohl, 
University of Utrecht, 
The Netherlands).
7 http://www.rda.nl/pages/adviezen.aspx
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of products and devices for human medicine and dentistry and 
for veterinary medicine”. this is in contrast to overall experi-
mental animal use, where toxicology and other safety evalua-
tions count for 8.7% of all animals used. Nearly a quarter of all 
dogs are used in “Research and development of products and 
devices for human medicine and dentistry and for veterinary 
medicine”, whereas “Production and quality control of products 
and devices for veterinary medicine”, “Biological studies of a 
fundamental nature” and “Diagnosis of disease” comprise the 
last quarter of total dog use. 
Our report will focus mainly on toxicological and other safety 
evaluations, biomedical research, and the development of prod-
ucts, but will mention also some examples of dog use which 
might not be that prominent, e.g., the dog as a genetic model. 
While most genetic work is carried out in mice, there are 220 
homologous hereditary diseases with uniform genetic muta-
tions shared by dogs and humans, where research on dogs is 
thought by some scientists to give deep insight, knowledge, and 
understanding of disease mechanisms and possible cures, e.g., 
bleeding disorders (haemophilia A and B), leukocyte adhesion 
deficiency, retinal degeneration (retinitis pigmentosum) and 
narcolepsy, while other scientists disagree.
5.2  The two-species paradigm
In 1965 the US FDA (Food and Drug Administration) intro-
duced the two-species paradigm, by which non-rodent species 
are required to provide sufficient data to pick up drug effects not 
observed in the rodent species. the second-species paradigm is 
still applied today, is mandatory in many cases, such as in the 
guidance of FDA, CHMP (Committee for Medicinal Products 
for Human Use), ICH (International Conference on Harmoniza-
tion), and the OeCD (Organization for economic Co-operation 
and Development). Pharmaceutical and agrochemical compa-
nies are presented with limited alternatives and commonly the 
thermore, the results of these considerations will not be univer-
sally valid but will differ significantly between societies. The 
importance of such a framework is that it provides a basis for 
discussion of animal welfare within a given society.
From the scientific point of view some people may conclude, 
that the dog represents an animal model of better validity for 
distinct research questions than other animal models, while 
other scientists strictly disagree. Given the presupposition that 
all animals have an intrinsic value, one must conclude that the 
choice of animal species for experimental purposes needs to be 
based on objective criteria such as model validity. On the other 
hand, an ethical justification for replacing dogs with another 
species may be difficult to find. However, it has to be acknowl-
edged that the emotional value of dogs for humans does result in 
a moral dilemma, not only within the broader society, but often 
as well for humans conducting experiments. 
While we therefore do not oppose the societal wish to direct 
special attention to the application of the 3Rs to the use of dogs 
in experimental research, we wish to emphasize that this ap-
proach may result in the use of less valid models or may require 
a higher number of animals to obtain reliable results.
5  Main areas of dog use
5.1  In general
Historically, the use of dogs as animal models for research and 
testing evolved because of their availability, size, and the ease 
of use. their anatomy and physiology are similar in many as-
pects to those of humans. As adapted from the european Com-
mission Staff Working Document8, which accompanied the Re-
port on the number of animals used for experimental and other 
scientific purposes, and shown in Table 1, more than 50% of 
all dogs are used in “toxicological and other safety evaluations 
8 http://ec.europa.eu/environment/chemicals/lab_animals/pdf/sec_2010_1107.pdf
Tab. 1: Areas of dog use 
Adapted from the Table “Number of animals used in experiments for selected purposes data of 2008 in Europe 27*”  
from the European Commission Staff Working Paper – Accompanying document to the Report from the Commission to  
the Council and the European Parliament on animal numbers used for scientific purposes 
Biological studies of a fundamental nature 1841
Research and development of products and devices for human medicine and dentistry and for veterinary medicine  
(excluding toxicological and other safety evaluations) 4405
Production and quality control of products and devices for human medicine and dentistry 157
Production and quality control of products and devices for veterinary medicine 2070
Toxicological and other safety evaluations (including safety evaluation of products and devices for human medicine  
and dentistry and for veterinary medicine) 11077
Diagnosis of disease 1111
Education and training 362
Other 316
All dogs used in 2008  21312
*(France reporting for 2007)
As stated in the Commission staff working paper: “Other” covers a wide range of experiments such as virology, immunology for 
production of monoclonal and polyclonal antibodies, physiology of fetal-maternal interaction in mouse gene transgenesis, oncological 
treatment, pharmaceutical research and development, combined drug testing and genetics.
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Tab. 2: The dog as 2nd species in EU legislation on chemicals, biocidal and plant protection products  
(Kindly provided by Kristina Wagner, German Animal Welfare Federation); emphasis added.
 
EU legislation 
REGULATION (EC)  
No 1907/2006 (REACH): 
Annex 9,  
information requirements  
for substance quantities of  
100 tonnes and more
 
 
REGULATION (EC)  
No 1907/2006 (REACH): 
Annex 9,  
information requirements  
for substance quantities of  
100 tonnes and more
Proposal for a REGULATION 
OF THE EUROPEAN 
PARLIAMENT AND OF THE 
COUNCIL concerning the 
placing on the market and use 
of biocidal products, (Political 
agreement reached in Council; 
2009/0076 (COD)) 
Annex II, Active Substances, 
Title 1, Chemicals
Regulation EC 440/2008 












OECD Test Guidelines for the 
testing on chemicals 
 
 
Draft Regulation laying 
down test methods / Data 
requirements for Active 
Substances in Plant 
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Test method / Study 
8.7.2. Pre-natal developmental toxicity study, one  
species, […] (B.31 of the Commission Regulation on test 
methods as specified in Article 13(3) or OECD 414).  
Specific rules for adaption from standard information required 
[…] A decision on the need to perform a study at this tonnage 
level or the next on a second species should  
be based on the outcome of the first test and all other relevant 
available data.
8.7.3. Two-generation reproductive toxicity, one species, male 
and female, […] 
Specific rules for adaption from standard information required 
[…]  A decision on the need to perform a study at this tonnage 
level or the next on a second species should be based on the 
outcome of the first test and all other relevant available date.
8.9.4. Further repeat dose studies  
ADS [ADS=additional data set] 
“Further repeat dose studies including testing on  






“The commonly used non-rodent species is the dog, […]” 
(This sub-chronic oral toxicity test method is a replicate of 
OECD TG 409) 
[…] The adult rat or rabbit may be used. […] 
Other species may be used but their use would require 
justification.  
[…] Note: in acute toxicity tests with animals of a higher 
order than rodents, the use of smaller numbers should  
be considered. […]
[…] The preferred species is the rat. 
Based upon the results of previously conducted studies  
other species (rodent or non-rodent) may be used. […] 
[…] For non-rodents a smaller number of animals, but at  
least four per sex per group, is acceptable. […]




5.3.2. Oral 90-day study 
[…] The short-term oral toxicity of the active substance to 
rodents (90-day), usually the rat, a different rodent species 
shall be justified, and non rodents (90-day toxicity study  
in dogs), shall always be reported. […]
5.5. Long term toxicity and carcinogenicity 
[…] If comparative metabolism data indicate that either rat 
or mouse is an inappropriate model for human cancer risk 
assessment, an alternative species could be considered if 
justified.
5.8.2. Supplementary studies on the active substance 
[…] a) studies on absorption, distribution, excretion and 
metabolism, in a second species, […]
Explicit  
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Changes in regulatory toxicology testing were often driven 
by tragedies (e.g., thalidomide; Kim and Scialli, 2011), and the 
liability of producers for their product, and the safety of volun-
teers and patients for the drug under investigation created the 
need for testing. every new incidence has added another patch 
of safety measures and guidelines, some of them dating back 
to the 1960s and earlier, based on the belief that more in vivo 
testing would solve the problem, but often largely unmodified 
with difficulties to adapt to new scientific advances (Hartung, 
2009a, 2011). testing should take place not as a default but on 
a need-to-know basis and there are cases where this paradigm is 
applied. An example is the guideline ICH S9, which regulates 
anti-cancer drugs for patients at the terminal stage, and neither 
long-term toxicity studies, nor fertility or pre- and post-natal 
studies are generally required. therefore, the need to perform 
studies on non-rodent species is limited here, and they are basi-
cally used for short-term studies and embryo-fetal development, 
mainly carried out in rabbit or monkey.
Chemicals 
In chemical development, studies with repeated dosing up to 
13 weeks are usually sufficient for filing. In some territories, e.g., 
Japan and Brazil, regulatory authorities still expect data covering 
6 months, which means that these studies are still conducted, 
even though they are considered unnecessary by the US and eU. 
Juvenile studies
toxicity studies for drugs intended for use in children and ado-
lescents represent another potential requirement of regulators 
to allow clinical pediatric drug development. the safety and 
efficacy for children and adolescents has not been studied in 
animals systematically until recently and the default conclusion 
was that a new drug is not recommended for use in children 
and adolescents due to lack of data. the design of these studies 
is often similar to those of repeat dose studies but using very 
young animals. the species is not explicitly prescribed, but the 
choice should be appropriate for evaluating toxicity endpoints 
relevant to the intended pediatric population and both sexes are 
obligatory. Standard non-clinical studies using adult animals, or 
safety information from adult humans, cannot always adequate-
ly predict these differences in safety profiles for all pediatric 
age groups, especially effects on immature systems that un-
dergo postnatal development, such as the brain, the pulmonary 
system, the kidneys, the reproductive system, the immune sys-
tem, the skeletal system and even other organs or tissues which 
may play a critical role in the pharmacokinetics of a medicinal 
product10. this point has to be taken into special consideration, 
because it might lead to new testing requirements for other dis-
tinct populations in addition to juveniles, e.g., the elderly, and 
diabetic or immune-compromised patients. 
Pesticides
For pesticide testing, one rodent and one non-rodent species are 
required. Dogs are used as non-rodent species for oral subchron-
dog is used as the second non-rodent species. In table 2 the 
“German Animal Welfare Federation” summarized eU legisla-
tion on chemicals, biocidal products and plant protection prod-
ucts that requires a second species, with special emphasis on the 
requirement of the dog. 
5.3  Regulatory toxicology 
Pharmaceuticals
An Industry/Welfare Steering Group (Smith et al., 2002) re-
viewed the areas where dogs are used. Safety pharmacology 
includes studies performed during the early development of a 
drug, before a first clinical trial. These studies may use dog tissue 
and organs for in vitro cardiovascular assessment. Non-recovery 
studies involving anesthetized dogs may be performed to assess 
hemodynamics, cardiovascular parameters, respiratory and renal 
functions. the less invasive model uses telemetered, conscious 
dogs to assess the cardiovascular system, thereby satisfying the 
regulatory demand of the safety pharmacology core battery. 
Cardiovascular side effects have been among the most fre-
quent causes for drug withdrawals, which eventually led to the 
first international regulatory guideline on safety pharmacology 
(ICH S7A)9 in 2000 to ensure the safety of human volunteers and 
patients participating in an early phase of clinical trials. though 
safety pharmacology testing was done before the guideline, a 
global harmonization component was added by its implementa-
tion. the “Safety Pharmacology Core Battery” was developed 
to assess drug effects on the functions of critical organ systems, 
e.g., cardiovascular, central nervous and respiratory function. In 
2005 “the Nonclinical evaluation of the Potential for Delayed 
Ventricular Repolarization (Qt Interval Prolongation) by Hu-
man Pharmaceuticals” (ICH S7B) was introduced. Both guid-
ance documents anticipated dog use with different emphasis of 
the role of in vitro and in vivo studies.
Dog studies are performed with single or multiple doses (fixed 
or ascending) to determine dose selection and to assess target 
organ toxicity, Maximum tolerated Dose and Dose Range Find-
ing (MtD/DRF). Often the study starts with an ascending dose 
in few animals until first signs of toxicity occur, is continued 
with a eIH (enter Into Humans) GlP (Good laboratory Prac-
tice) study requiring a sufficient number of animals to assess 
target organ toxicity and reversibility, determine the safe start-
ing dose, derive safety margins and set the ceiling exposure to 
support clinical planning, and ends with a long-term GlP study 
with a statistically valid number of animals to support long-term 
clinical studies and marketing. Repeat Dose is the pivotal study 
in a regulatory package in pharmaceutical development and du-
rations of 14 days to 1 month, 3 months, and 9 to 12 months 
are generally used. In some cases, some of these studies may 
be omitted depending on the clinical program (duration of hu-
man studies) or the therapeutic indication (6 months studies are 
sufficient for some countries or indications). Study designs are 
generally well defined and include extensive in-life monitoring, 
e.g., eCG (electrocardiography), hematology, clinical chemis-
try, ophthalmology and detailed histopathology. 
9   http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
10 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003305.pdf
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ing the pharmacological activity of the drug, the pharmacoki-
netic profile allowing sufficient exposure, and analysis of the 
metabolism and its similarity to humans. Best scientific practice 
and therefore enhanced consumer safety requires using the best 
model, not the one that is most easily available. It always should 
be kept in mind that species choice needs to be specific to the 
compounds under investigation. that would also suggest that 
academia and industry should publish their findings to avoid 
unnecessary duplicative testing. Some examples of limitations 
in the use of dogs are given in table 3.
the use of dogs as a second species in safety evaluations is 
closely linked to a long-lasting discussion on multiple species 
toxicity testing in general. Retrospective analyses of the addition-
al value of dog studies over rodent studies have been published 
in the area of pesticide testing, where extensive information is 
available in several national registers (Gerbracht and Spielmann, 
1998; 2001; Box and Spielmann, 2005; Kobel et al., 2010). Such 
studies indicated early on, that for instance mouse data provide 
no gain of knowledge, when rat and dog data are available. How-
ever, detailed analysis of chronic and subchronic toxicity studies 
also indicated that the dog is the more sensitive species (when 
compared to rats) in about 15% of all cases. thus, the dog studies 
contributed clearly to the definition of the NOEL (no observed 
effects level). Since the NOel is used as point of departure for 
safety regulations, dogs were required in the field of pesticides 
according to these retrospective surveys of several hundred com-
pounds (Box and Spielmann, 2005; Kobel et al., 2010). However, 
more detailed analysis also examined the need for long-term (12 
month) dog studies, in addition to shorter studies (90 days), and 
the conclusion of international regulatory experts was that dogs 
as second species for long term studies beyond 13 weeks are dis-
pensable (Kobel et al., 2010; Dellarco, 2010). 
Some retrospective data are also available from the field of 
pharmaceuticals. A study by Olson (Olson et al. 2000) com-
pared human toxicities of about 150 drugs with the respective 
preclinical toxicity data obtained in rodent and non-rodent spe-
cies. they used this data base to investigate the predictive value 
of the two-species approach. they found that a better test sen-
sitivity was obtained when data from two species (e.g. dog and 
rat) were combined. Non-rodent data from either non-human 
primates or dogs taken together with rodent data predicted hu-
man toxicity in 71% of all cases, while rodent data only pre-
dicted 43% of human toxicities.
this study is often taken as evidence that the non-rodent spe-
cies is indispensable for human safety assessment, and that in-
clusion of several species increases test sensitivity. However, it 
is also well-known that this approach invariably decreases test 
specificity and leads to a large number of false positive results 
(Hartung, 2009a). As the authors of the Olson report themselves 
admitted, “A more complete evaluation of the predictability as-
pect will be an important part of a future prospective survey.” 
A statistician elaborated on this in 2008 (Matthews, 2008), and 
concluded: when the correct definitions of sensitivity, specifici-
ty and likelihood ratio are used, “the data provide no statistically 
credible evidence that these animal models [dogs and monkeys] 
contribute any predictive value, either separately or in combina-
tion.” therefore, some scientists conclude that published data 
ic and chronic toxicology studies. In many cases, the dog ap-
pears to be more sensitive than the rat, i.e., they show effects 
at lower doses. Notably, new regulations have been adopted in 
the US that eliminate the one-year chronic toxicity study in the 
non-rodent; the subchronic 90 day study is considered sufficient 
because meta-analysis showed that there is no significant ad-
ditional information obtained from a longer study (Kobel et al., 
2010). eU regulations are also changing to allow a 90 day study 
without the need for a one year study, but unfortunately Japan 
and Brazil still require the one year test. thus, a european or US 
company intending to sell to the Japanese or Brazilian market 
must still perform a one-year study in the non-rodent, i.e., dog.
Non-pharmaceuticals
For some non-pharmaceutical products, e.g., agrochemicals and 
biocides, it is explicitly indicated that the dog is the first choice 
as a non-rodent species for toxicity testing. this approach ap-
pears to be based on historical experience and tradition rather 
than scientific rationale, but is strongly supported by Guidelines. 
OeCD 409 demands: “the commonly used non-rodent species 
is the dog, which should be of a defined breed” and OPPTS 
870-3150 states specifically: “The commonly used non-rodent 
species is the dog, preferably of a defined breed; the beagle is 
frequently used. If other mammalian species are used, the tester 
should provide justification/reasoning for his or her selection.” 
5.4  Other areas
Non-clinical tests on dogs are also conducted for certain alimen-
tary products and veterinary medicines. Dog research is also 
done on diseases and conditions particular to dogs, including 
chronic pain, hip dysplasia and behavioral diseases. Conditions 
in specific breeds like mast cell tumors in Labrador Retrievers, 
rage syndrome in English Springer Spaniels or inflammatory 
bowel disease in Boxers are among the numerous examples that 
have prompted specific studies.
6  The selection of the second species
Directive 2010/63/eC, Recital 13 states that “the choice of 
methods and the species to be used have a direct impact on both 
the numbers of animals used and their welfare. the methods 
selected should use the minimum number of animals that would 
provide reliable results and require the use of species with the 
lowest capacity to experience pain, suffering, distress or lasting 
harm that are optimal for extrapolation into target species.” 
traditionally, the dog is considered the non-rodent species of 
first choice, due to the fact that Beagles are purpose-bred and 
easily available and knowledge on their physiology is extensive. 
the choice of non-rodent species in toxicological programs has 
to be specifically justified based on scientific evidence relating to 
the predictability of the animal model for the specific function. 
All available information, like in vitro data and state-of-the-art 
literature, must be taken into account to ensure the choice of the 
best model. Species selection must be made on a case-by-case 
basis, indicating scientific justification, ethical perspectives, 
technical considerations, and regulatory acceptability, weigh-
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style and living environment. Certainly dogs have influenced 
humans but humans have influenced dogs much more by selec-
tive breeding, therefore enhancing certain phenotypes. Studies 
are ongoing in canine science, cognitive ethology, dog-human 
communication as well as the dog-wolf comparison (Gácsi et 
al., 2005) exploring the dog as a natural model for human be-
havior (Miklósi, 2007). Dogs may help to trace human behav-
ioral evolution by evaluating human species-specific behavio-
ral traits that possibly evolved after the “pan” and “homo” split 
(approx. 6 million years ago) with those of the dogs having 
evolved around 15-25,000 BC. this convergence in dog social 
behavior led to a nearly symbiotic relationship between these 
two species. the natural environment for a dog is the one of-
fered by a human being. 
this idea led to studies in which an association of a poly-
morphism in the dopamine D4 receptor gene and the (hyper-) 
activity of dogs was discovered (Hejjas et al., 2007), which 
in turn led to observations regarding human ADHD (attention 
deficit hyperactivity disorder). Furthermore, a potential cure 
may have been identified, as indicated by the discovery that 
dietary supplementation with medium-chain triglycerides re-
sulted in long-lasting cognition-enhancing effects in aged dogs 
(Pan et al., 2010).
For some scientists dogs may provide a good “natural model” 
for studying behavior, while others disagree. Nevertheless, if 
these studies are conducted, emphasis has to be put on the meth-
ods used to measure the behavioral phenotype. these methods 
should lead to the development of ecologically and socially 
valid tests, and the introduction of non-invasive testing methods 
that are the basis for a sound analysis. these kinds of studies 
may be helpful to develop tools to determine and measure ani-
mal welfare, which would be a prerequisite to further improve-
ment in the area of refinement. 
8  Canine models of human inherited disorders
Dogs are being used in attempts to further understand and eluci-
date human diseases and contributions of about € 12 million are 
given by the eU for canine disease genetics12, acknowledging 
the potential value for human health. Some people may assume 
that dogs are clinically and physiologically closer to humans 
to demonstrate the need for dogs in drug safety testing is lack-
ing, and that it is possible to achieve a reduction and refinement 
in dog use without compromising human safety (Broadhead et 
al., 2000). Since both drug testing and also general biological 
knowledge have changed considerably during the last 10 years, 
new comprehensive retrospective evaluations would shed more 
light on the predictivity, sensitivity and specificity aspects of 
using dogs in safety evaluations. We suggest such studies, ap-
plying the principles of evidence-based toxicology (Hofmann 
and Hartung 2006; Hartung, 2009b), to provide a more solid 
scientific basis for future discussions on this topic.
In order to respond to public concerns toward laboratory dogs 
an EU FP6 Specific Support Action (SSA) project called “RE-
tHINK” was initiated to investigate the feasibility of the mini-
pig as an alternative model for regulatory toxicity testing. Re-
tHINK was a multinational project, co-funded by the european 
Commission, consisting of 5 Working Groups, where several 
invited experts from the european Union reviewed the impact of 
toxicity testing in mini-pigs over the period 2006-2008 including 
an evaluation of the potential 3Rs contribution. the results were 
published in 2010 in a special issue of the Journal of Pharmaco-
logical and Toxicological Methods (Forster et al., 2010). 
Over the last ten years there has been a reduction of the use of 
dogs and a concurrent increased interest and acceptance of mini-
pigs as an alternative non-rodent species in accordance with the 
RetHINK conclusions. they recognized areas where a case-by-
case analysis will favor the use of the mini-pigs over the dog in tox-
icology and drug development. the workshop participants agreed 
that replacing one sentient being by another equally sentient one 
cannot be called a 3Rs initiative, and should not be the final goal. 
An eFPIA document of species selection is currently in prep-
aration and builds on the “Points to Consider” document pub-
lished jointly in 2002 in the UK by the ABPI (Association of 
British Pharmaceutical Industry) and the Home Office11.
7  The dog as a new “natural model”  
for human behavior
As already mentioned, humans and dogs have coexisted in 
close proximity for a long time, sharing the same nutrition, life 
Tab. 3: Limitations for the use of dogs with examples of oversensitivity
Limitations for the use of dogs  Examples of oversensitivity
Convulsions dose-limiting 
Emesis* insufficient exposure or erratic dosing 
Non-steroidal anti-inflammatory drugs GIT lesions 
Vasodilators & anti-hypertensives arteriopathy & cardiotoxicity 
Hormones females may be very sensitive to estrogens and anti-estrogens 
Drugs causing histamine release dose-limiting due to pseudo-allergy
*Emesis is controversially discussed (du Sert et al., 2011).
11 http://www.abpi.org.uk/our-work/library/guidelines/Pages/non-rodent.aspx
12 http://www.eurolupa.org/
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tox-21c (NRC, 2007; Krewski et al., 2010), i.e., the vision put 
forward by the 2007 publication of the US National Research 
Council “Toxicity Testing in the 21st Century: A Vision and a 
Strategy”, offers a completely new way of approaching toxicol-
ogy by identifying pathways of toxicity (Hartung and McBride, 
2011, Andersen et al., 2011), looking at modes of action, and de-
veloping in vitro tests which are directly guided to the mecha-
nism of toxicity instead of the “black box approach” the animal 
provides. Though this vision has no aspect specific to dog use, 
it has created a spirit of optimism that the replacement of cur-
rently conducted animal testing by mechanistically based higher 
throughput tests can be possible (Hartung, 2008a; 2010b; Har-
tung and Koëter, 2008; Hartung and leist, 2008), using human 
cells (leist et al., 2008; Kuegler et al., 2010), response pathways 
(Alon, 2007), and evidence-based procedures (Hoffmann and 
Hartung, 2006; Hartung, 2009b) to develop scientifically sound 
“Integrated testing Strategies” (Jaworska and Hoffmann, 2010).
there are ongoing efforts in which experts from animal wel-
fare organizations work together with regulators to produce new 
drug development guidelines for the use of alternative methods 
to replace animal use.
10  Reduction
the approach to the reduction of dog use was addressed by a 
UK “Industry/Animal Welfare Initiative to minimize dog use 
in preclinical toxicology” following a workshop on “the dog 
in regulatory toxicology” (Smith et al., 2002). A Consortium 
of european pharmaceutical companies, including the Fund for 
the Replacement of Animals in Medical experiments (FRAMe) 
and the Royal Society for the Prevention of Cruelty to Animals 
(RSCPA), was formed, supported by the european Federation 
of Pharmaceutical Industries (eFPIA) and the Association of 
the British Pharmaceutical Industry (ABPI).
the project was divided into three phases covering (1) Best 
practice in study design (Refinement/Reduction/Replacement), 
(2) Industrial co-operation and data sharing (Reduction), and (3) 
Assessing the need for particular studies (Replacement).
In phase 1 (Best practice in study design) different approach-
es were investigated:
– Design of preliminary studies
– Group sizes for repeat-dose studies
– Use of single sex studies
– the need for recovery groups
– the use of control animals
– Overall program design
Preliminary studies are usually conducted outside of the regula-
tory framework because they are used to collect information for 
future studies, particularly dose range finding and the maximum 
tolerated dose. through analysis of an industry questionnaire 
the group found that there was no consensus on design or power 
of the studies conducted. Furthermore, in 12 responding com-
panies, 15 different study designs were used with variations in 
many design aspects and in numbers of dogs. the results opened 
than tiny rodents and that human and canine diseases progress 
more similarly, others may disagree.
The various dog breeds carry unique breed-specific variations 
in morphological and behavioral traits and more than 600 genet-
ic disorders are described with around 70% of the diseases hav-
ing corresponding human conditions. Dogs have the advantages 
of a large pedigree and a unique population history of around 
9000 generations with a unique breed structure of more than 
400 genetic isolates (Karlsson and lindblad-toh, 2008).
these characteristics may lead, for some scientists, to the 
conclusion that the dog might be a natural model for human dis-
orders like epilepsy, separation anxiety, obsessive-compulsive 
behavior, and aggression. A large dog DNA bank has already 
been established where several new loci and genes have been 
identified for different diseases, most of them as new candidates 
for corresponding human disorders. the process is non-invasive 
and requires only the dog owner’s consent, a blood sample and a 
phenotype characterization by completion of a questionnaire. 
this knowledge opens a new area of discussion on the use 
of dogs. One option might be to simply exclude animals with 
genetic defects from breeding, but this may raise new ethical 
issues, because pharmaceutical companies and biomedical re-
search scientists might consider using these animals under pur-
pose-bred conditions to find and develop new drugs.
9  Replacement
Replacement, as introduced by Russell and Burch as a part of 
the 3Rs principle for humane experimental technique in 1959 
(Russell and Burch, 1959), refers to methods that avoid or re-
place the use of animals, where they would otherwise have been 
used. Replacement methods can be absolute replacements – 
techniques that do not involve live animals at any point, such 
as computer modeling, cell culture and tissue engineering or 
other in vitro methodologies – or relative replacements, which 
replace the use of (higher) animals by non-sentient species13. 
In Recital 10, European Directive 2010/63/EU clearly identifies 
full Replacement procedures on live animals for scientific and 
educational purposes as the final goal, “as soon as it is scientifi-
cally possible to do so.” Furthermore, the Directive states in its 
Article 4, Part 1: “Member States shall ensure that, wherever 
possible, a scientifically satisfactory method or testing strategy, 
not entailing the use of live animals, shall be used instead of a 
procedure.” 
Unfortunately, there are no methods or strategies available at 
the moment to ensure a full Replacement of experiments on dogs, 
so the main research effort and funding should be directed to-
wards the development of such methods. Scientific and technical 
progress are moving fast and new and promising methods are 
being developed constantly, so it will be a question of identifying 
or promoting those that are suitable to address scientific ques-
tions and satisfy the needs for more humane and evidence-based 
safety testing. these methods and techniques also will need to be 
internationally accepted and to be integrated in testing strategies. 
13 http://www.nc3rs.org.uk/page.asp?id=7
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ures should be taken to ensure the supply of animals does not 
exceed demand. Dog housing should aim to meet the physical, 
physiological, behavioral and social needs and as a guiding 
principle, housing and husbandry should be managed in order 
to allow animals to perform a wide range of species-specific 
behaviors.
the dog is a social, macro-osmatic, neophyllic (inquisitive) 
omnivore that, when feral, can range over large areas (28.5 km2). 
Research on carnivores shows that those with large ranges tend to 
fare worse in captivity (Clubb and Mason, 2003; Hubrecht et al., 
1992). Minimum space allowances set down in codes of practice 
or legislation tend to be relatively small (tab. 4), therefore, it may 
be difficult to provide kenneling in a research environment that 
meets the dog’s needs in total.
even in the largest of these (4.5 m2) some dogs develop be-
havioral abnormalities. What is put into the space in terms of 
enrichment, etc., may well be more important than a few square 
centimeters of space; however smaller spaces provide fewer op-
portunities to provide enrichment, complexity and control for 
the dog.
Outdoor runs may be beneficial in providing greater com-
plexity and interest (Hubrecht, 1993; Spangenberg et al., 2006). 
Dogs should be housed in socially harmonious pairs or groups 
and additional human socialization should be provided as it has 
been shown that petting lowers blood cortisol (Hennessy et al., 
1998; tuber et al., 1996). Social isolation should be avoided. 
environmental enrichment is crucial (Hubrecht, 1995) and en-
richment items should be provided and presented in a way as to 
maintain interest and activity to avoid frustration and boredom 
(Pullen et al., 2010). the effects of enrichment should be closely 
monitored. Chewing is an important behavior and items should 
be provided to meet this need. Social enrichment (both dog-dog 
and dog-human) and adequate physical and mental stimulation 
are also crucial, therefore exercise periods should be provided 
ideally on a daily basis. Noise levels can be a problem, but can 
be reduced by facilities that meet the animal’s needs and by suit-
able building design. Dogs should never be debarked.
Stereotypies are an indicator that there is a welfare issue 
(Clubb and Mason, 2003) and the aim should be to avoid their 
occurrence rather than dealing with them once they have ap-
peared. Behavior of dogs should be monitored in order to detect 
behavioral abnormalities and other signs of poor welfare. Indi-
cators of acute and chronic stress are summarized in table 5 as 
published in Beerda et al. (1997, 1998, 1999a,b).
If dogs do develop behavioral abnormalities, housing and 
husbandry practices should be examined and changed so that 
such behaviors are eliminated. 
to improve the welfare of dogs used in biomedical research 
and testing, more research is needed. Observational studies to 
understand responses to changes in husbandry via preference 
and choice tests plus motivational demand studies to understand 
the cognitive state may be useful. the dog’s olfactory sense is 
103-108 times more sensitive than ours, but there have been 
relatively few studies on olfactory enrichment (Graham et al., 
2005) or on auditory enrichment (Wells et al., 2002).
Dogs’ vision is good (Neitz et al., 1989), and kennels with 
clear sight lines out of the dog’s enclosure are beneficial in 
the opportunity to develop a harmonized design by reviewing 
the intended purpose of the study with regard to numbers of 
animals and outcome of the 14- or 28-day study. the primary 
purpose is dose selection (high dose) for the pivotal repeat dose 
study and the secondary purpose is the detection of serious tox-
icity. In this way candidate drug selection can be confirmed and 
an estimation of compound requirements and toxicokinetic data 
can be obtained. thus, a preliminary prediction of dose levels 
for 14- or 28-day studies can be made based on a low number of 
animals used (9-12 animals showed best results). After a thor-
ough review, harmonization of the principal study design was 
proposed, which led to a reduction in dog use by applying the 
optimized design and endpoints (Smith et al., 2005)
Phase 2 consisted of a data-sharing initiative to avoid un-
necessary duplication of studies within pesticide, chemical and 
pharmaceutical sectors. the authors also supported the devel-
opment of a central database of animal experiments, including 
a vehicle database containing in vivo toxicological information 
on non-active formulation ingredients (vehicles, solvents, ex-
cipients, preservatives, etc.) and selected chemicals, in terms of 
its potential to share qualitative and quantitative data between 
interested parties. the database is hosted by lhasa ltd. It of-
fers free access for collaborating companies and operates with a 
search fee for outsiders. 
In phase 3, the assessment of the need for particular studies 
took place and suggestions were to eliminate the terminal 3 or 6 
month study by maximizing data from safety pharmacology in 
1 month studies, using interim readout from the 9 or 12 month 
study combined with non-destructive sampling. Unfortunately, 
it is necessary to wait for the outcome of biomarker/-omics 
projects before proceeding with this part of the project. 
the impact of these best practices in MtD/DRF study design 
initiative was estimated to account for a reduction by 40-120 
dogs/company/year, the elimination of acute toxicity testing 
(for Japan) saves 8-16 dogs/company/year and standardization 
of group sizes for repeat dose studies resulted in small gains. A 
2006 survey in the UK showed that the removal of control re-
covery groups might be able to save 120 dogs per year, but some 
companies are still concerned about the scientific and regulatory 
repercussions of that question (Smith et al., 2007). 
11  Refinement 
there are a number of resources already available to assist with 
refinement of dog care and use (Wells, 2004; Hubrecht and Kirk-
wood, 2010). they provide an extensive collection of recom-
mendations on housing, physical environment, food and feed-
ing, environmental enrichment, exercise, health and hygiene, 
breeding, balancing supply and demand, grouping, transport, 
handling and restraint, procedures, long-term use, re-homing, 
staff training and areas for future research to refine further dog 
husbandry and care (BVAAWF/FRAMe/RSPCA/UFAW Joint 
Working Group on Refinement, 2004). 
the main breed used in laboratories is the Beagle and, in 
europe, animals used in experiments must be purpose-bred. 
to minimize the creation of surplus animals all possible meas-
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the International Conference on Harmonization of technical 
Requirements for Registration of Pharmaceuticals for Human 
Use (ICH), the International Cooperation on Harmonization 
of technical Requirements for Registration of Veterinary Me-
dicinal Products (VICH) and the World Health Organization 
(WHO). 
AAAlAC (Association for Assessment and Accreditation of 
laboratory Animal Care International), is an international or-
ganization which promotes animal welfare through an accredi-
tation program. AAAlAC grants accreditation if the applicant 
meets or exceeds the standards set forth by the three following 
references plus additional reference documents:
1. “8th edition of the Guide for the Care and Use of Laboratory 
Animals”, NRC (2011);
2. “Guide for the Care and Use of Agricultural Animals in Re-
search and Teaching” (Ag Guide), FASS (2010); 
3. “european Convention for the Protection of Vertebrate Ani-
mals Used for Experimental and Other Scientific Purposes”, 
Council of europe (etS 123).
AAAlAC’s international accreditation program is carried out 
mainly by independent experts, who actively visit sites, provide 
advice and recommendations, and award accreditation. Profes-
sional and continuous improvement of the animal care and use 
program, based on re-visits occurring every three years for con-
tinued accreditation, helps to raise animal welfare standards in 
daily practice. A retrospective analysis of AAAlAC site visits 
in europe from 2003 to 2008 revealed that most frequently the 
areas that needed improvement before accreditation could be 
granted were in the animal environment and veterinary care, and 
within these areas the subcategories “behavioral management, 
structural and social environment” and “preventive medicine, 
surveillance, diagnosis” were most prominent. Institutions that 
apply for accreditation have to submit a program description 
which typically has a volume of 100 pages or more, and host 
the site visitors who perform an in-depth review of the animal 
care and use program. Currently there are over 60 AAAlAC-
accredited european institutions, the majority pharmaceutical 
providing them with the ability to predict events and exert a 
degree of control. Windows can be useful in providing such 
sightlines, and structures, such as platforms, provide addition-
al complexity. 
Other areas for future research identified by the Joint Working 
Group were: 
– the relationship between welfare and the physical and social 
environment
– economical and practical ways of enriching the kennel
– the relationship between pen size, number of individuals 
and behavior
– Ways to prevent and manage aggression
– the demand for different toys and chews
– The influence of early experience on behavior in laboratory 
Beagles
– the psychological and physiological effects of transport 
As for many species, many indicators of welfare can be taken 
(behavioral, physiological) but these still have to be interpreted 
and this can be difficult. When making so-called improvements 
care has to be taken to ensure that real welfare improvements 
have been made. 
there are various national and international standards that 
provide minimum standards for dog housing. In europe there 
is the Council of europe Convention etS 123 and european 
Community Directive 2010/63/eU, which will be enacted on 
January 1, 2013, and more internationally there are the Organi-
zation for economic Co-operation and Development (OeCD), 
Tab. 4: Comparison of minimum space allowances for 
medium sized dogs
Minimum space allowance by guidelines m2 feet2
1996 NRC Guide 1.1 12
2011 NRC Guide 1.1 12
1986 UK (1 or 2 animals) 4.5 48.4
2010 EU (1 or 2 animals) 4.0 43.1
Tab. 5: Stress indicators in dogs
Indicators of acute stress  Indicators of chronic stress 
Low posture  Low posture 
Body shaking  Increased autogrooming 
Crouching  Paw lifting 
Oral behaviors (tongue out, licking muzzle, swallowing)  Vocalizing 
Restlessness  Repetitive behavior 
Yawning  Coprophagy 
Heart rate change  high cortisol/creatinine ratio 
Increased cortisol/creatinine ratio  increased catecholamines 
Peripheral leukocytosis  When stimulated: 
 High levels of locomotor activity  
 Increased levels of change of active state 
 Body shaking 
 Yawning 
 Ambivalent postures 
 Displacement behavior  
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analysis of what results are actually used for regulatory decisions 
can guide to develop selective assays. As an example (not involv-
ing dogs), a retrospective analysis of reproductive toxicity studies 
was mentioned, where the outcome showed, that in 80% of the 
cases testis toxicity was the reason for classification (Bremer et 
al., 2007). this is already assessed in general toxicity repeat-dose 
studies and is easier to model in vitro than the whole reproductive 
cycle. Another retrospective study on neurovirulence testing in 
monkeys showed that the test was unable to discriminate between 
the attenuated, safe vaccine virus and virulent wild type strains 
and was therefore banned (IABS, 2005).
A suggestion from the animal welfare side was to use the 
“blank paper” approach: given the assumption that no suitable 
test exists and toxicity studies would be developed de novo with-
out historical prejudices, using newest technologies, and taking 
into account the state-of-the-art knowledge without considering 
existing liability issues or regulatory requirements. Such an ac-
tivity would require an intense literature research for evidence-
based information, including data from pharmaceutical industry, 
and might lead to a whole new set of in vitro approaches. 
12.2  Reduction
In the area of reduction clear statements were made, mainly by 
the pharmaceutical industry based on their experience, which 
every experimenter, study director or managing team should 
follow. A guidance document might be useful that includes the 
following points:
– Plan properly and upon demand (most drugs do not make it 
into clinical trials).
– Avoid in vivo screening and parallel testing as much as pos-
sible, which requires the management to be on board.
– Choose species case-by-case, not based on preceding choice, 
costs or availability.
– Mini-optimize early studies (1 sex, N=1/sex; short).
– Use fewer animals per project by combining studies and us-
ing interim sampling or biopsies.
– Avoid control animals whenever possible (e.g., in reversibil-
ity group).
– Challenge the need for reversibility data in studies, as re-
versibility does not distinguish adverse from non-adverse ef-
fects.
– Consider integrated approaches whenever possible, e.g., in-
clude safety pharmacology parameters in general toxicology 
to prevent the need for additional repeat-dose studies.
– Start at young age of animals to cover potential juvenile is-
sues and waive stand-alone juvenile studies whenever appro-
priate.
– Use the animals in multiple studies, e.g., in MtD studies 
with insignificant toxicity. 
– think globally by performing GlP studies with globally ac-
ceptable design in order to prevent any need for repetition.
– exchange data within industry, e.g., experience with spe-
cies selection, excipients and findings irrelevant to humans 
(“false positive compounds”). 
– Use state-of-the-art methods to gain as much valuable data as 
possible with a minimum of stress, e.g., wireless data collec-
tion systems. 
companies and contract research organizations (CROs), though 
also academic and other institutions, participate in the accredita-
tion program. In selecting a CRO, AAAlAC-accreditation is an 
important quality marker for animal welfare.
12  Discussion and suggestions
As the workshop participants had backgrounds from pharmaceu-
tical and pesticide industries, CROs, the regulatory arena, animal 
welfare organizations and academia, different views and experi-
ences were brought into the discussion, and some opinions were 
controversial. Nevertheless, trying to find a way toward consen-
sus gave rise to many ideas, which are summarized here. each 
individual participant does not necessarily back each idea.
It was agreed that this workshop is evidence that industry and 
animal welfare groups can work together towards achieving 
best practices and furthering the 3Rs concept. this depends on 
building trust and confidence, which are considered essential 
if ideas and data are to be shared. the power of a consortium 
consisting of various groups from different backgrounds to in-
fluence legislation and regulators is synergistic, and the value 
of sharing information is priceless. this is the way considered 
best to affect a change in ensuring harmonized best practice and 
animal welfare issues in the future. 
Unfortunately, methods to fully replace the use of dogs and 
other animals are not available yet for some areas of research 
and safety testing. It is therefore obviously desirable to develop 
replacement methods and meanwhile reduce the numbers of 
dogs used in experiments. It is not more ethical to substitute 
dogs with another equally sentient species, e.g., mini-pigs. 
therefore, an important task is to further reduce dog use and op-
timize laboratory conditions by refinement approaches. In order 
to further the refinement of work with laboratory dogs and other 
animals, CAAT announced the creation of an Industry Refine-
ment Working Group and preparatory discussions so far include 
twelve companies. A grant from the Klingenstein Foundation 
allows CAAt to serve as the secretariat for this initiative, which 
may help to give the suggestions and recommendations from 
this workshop a direct impact and follow-up.
12.1  Replacement 
the Replacement of experiments on animals, including dogs, is 
the final goal in both research and testing. Therefore, a key point 
of action will be the identification and development of suitable 
Replacement methods from areas like computer modeling tech-
niques, in vitro methods, cell culture and tissue engineering that 
will also be fit for international acceptance and could be inte-
grated in testing strategies, test guidelines and data requirements 
or that can be widely used in biomedical research. extensive 
funding will be needed and should be made available. Data-bases 
should be created using a weight of evidence approach that also 
includes a cost-benefit analysis and ethical reviews. 
Furthermore, a working group should be formed to identify 
more opportunities to conduct retrospective studies, in order to 
determine the initial value of the experiment, the read-out, and 
the practical benefit for humans. The point was made that closer 
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cal and there should be a minimum requirement for educational 
training as well as assessment of the competence of animal care-
takers, experimenters and their trainers, as described in the new 
Directive 2010/63/eU.
An area where information is still needed, and which could 
be addressed by additional workshops, is the requirement for 
juvenile testing, because this may create a whole new point of 
view on the need of animal testing.
12.5  Regulatory acceptance and globalization
Regulatory acceptance and globalization are major factors 
to take into account. As long as one market requests a certain 
study, this type of test still will be carried out as seen in the 
case of the one year study for pesticides, which has been aban-
doned by the eU and US, but is still required in Brazil and Ja-
pan. A formal meeting with regulators from different countries 
is being discussed by CAAt-US, at which existing data can be 
presented and decisions to adopt international standards can be 
discussed.
Harmonization of minimum standards and data requirements 
and adaptation to scientific and technical progress at a national 
and international level is considered essential. this should be 
done in europe through the european Commission and more 
internationally through the respective organizations, like the 
OeCD, the ICH and the VICH. 
Furthermore it was recognized that regulatory authorities are 
starting to be more confident in the quality of non-clinical data 
and more flexible in considering non-standard approaches. New 
experimental models including the use of novel tools are now 
more readily accepted by regulatory authorities. 
13  Recommendations
Increase knowledge 
1. Observational studies to understand natural and kenneled be-
havior of dogs using preference and choice tests taking into 
consideration the different stages of their life
2. Identification of the possibilities for retrospective studies, to 
determine the initial value of the experiment, the read-out 
and the practical benefit for the human
3. Given the lack of data assessing the predictive power from 
dog to humans for a large number of drugs or drug candi-
dates, a large retrospective analysis should be carried out
4. Individual identification of severe procedures performed 
with laboratory animals with the goal to change them into 
mild procedures
Guidance documents
1. Replacement guidance document
2. Reduction guidance document 
3. “Animal Welfare best practice document” achieved by an 
evidence-based approach creating an animal welfare score or 
indicator
– Publish and educate.
– Share control groups for parallel running studies, encourage 
CROs to do so as well. Sponsors can easily share control data.
– Do not try to save money by outsourcing into uncontrollable 
environments.
Summarizing the above mentioned points and developing a best 
practice guidance document would be a starting point for the 
above mentioned Industry Refinement Working Group.
12.3  Refinement of husbandry and care taking 
Given the existing knowledge and an international accreditation 
body some improvements in the area of refinement already have 
been achieved but the main question remains: How should we 
define animal welfare, what should be the minimum standards, 
and how can we successfully measure applied animal welfare?
It was agreed that more information is needed and observa-
tional studies assessing laboratory animals in general should be 
carried out, taking into consideration the different stages of their 
life, starting with the breeding conditions, their socialization, 
needs when kept in stock, and their behavior under experimen-
tal conditions leading to an “Animal Welfare best practice doc-
ument”. this study should include state-of-the-art approaches 
such as monitoring by video-surveillance, and offering the ani-
mal preferences to understand what it really needs. 
this can be done by a step-by-step or a gap analysis but should 
definitely lead to an evidence-based refinement approach. The 
creation of an animal welfare score, similar to the trauma score 
assessed in emergency settings in hospitals, was suggested. 
the animal welfare score could be like a checklist of different 
measures, with the distinct purpose of leading to a profile of a 
balanced or at least un-distressed animal when following the 
minimum recommendations.
12.4  Refinement of procedures
The workshop participants also identified a need to take action 
regarding the severity of procedures. As discussed before, no 
publicly available data describes commonly used procedures. A 
study should be financed and conducted to identify severe pro-
cedures as defined in the severity classification in Annex VIII 
of Directive 2010/63/eU14 and experts should confer to make 
recommendations that would lessen their severity. 
Humane endpoints need to be better defined; especially the 
termination criteria in the maximum tolerated dose study, which 
can inflict a severe level of distress and pain. Working groups 
currently exist, e.g., eFPIA/NC3Rs acute toxicity project, which 
could be encouraged to address this topic, taking into considera-
tion the OeCD Guidance Document 1915 on the recognition, 
assessment and use of clinical signs as humane endpoints for 
experimental animals used in safety evaluation. 
the use of non-invasive methodologies, like Pet scan im-
aging, as well as interim sampling, biomarker studies, biopsies 
instead of killing, are preferred. 
Well-trained, empathetic staff is one of the most important as-
sets for animal welfare; therefore, training procedures are criti-
14 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:En:PDF
15 http://www.imm.ki.se/sft/pdf/OECD19.pdf
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